Black Diamond Therapeutics, Inc. (BDTX)
2.67
+0.12
(+4.71%)
USD |
NASDAQ |
Dec 24, 16:00
Black Diamond Therapeutics Cash from Investing (Quarterly): 8.59M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Johnson & Johnson | -542.00M |
| Puma Biotechnology, Inc. | 0.506M |
| Cidara Therapeutics, Inc. | -176.47M |
| Oric Pharmaceuticals, Inc. | -110.54M |
| Acumen Pharmaceuticals, Inc. | 40.51M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -7.85M |
| Cash from Financing (Quarterly) | 0.134M |
| Free Cash Flow | 21.35M |
| Free Cash Flow Per Share (Quarterly) | -0.1379 |
| Free Cash Flow to Equity (Quarterly) | -6.768M |
| Free Cash Flow to Firm (Quarterly) | -7.85M |
| Free Cash Flow Yield | 14.03% |